Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
NA Estradiol Estrace 0.5mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Altretamine Hexalen 50 mg Chemotherapy Alkylating Agent Triazines Yes 1990 2019 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 2.5 mg Hormonal Therapy Estrogen Yes 1977 In Use
C9448 Netupitant/Palonosetron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Apr 1, 2015 Jun 30, 2015 No Longer Used
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2012 Dec 31, 2012 No Longer Used
J7527 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2013 In Use
S0156 Exemestane Aromasin 25 mg Hormonal Therapy Aromatase Inhibitor Yes 1999 Jan 1, 2001 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
NA Testolactone Teslac 250 mg Hormonal Therapy Androgen Yes 1970 Jun 25, 2005 No Longer Used
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Ruxolitinib Jakafi 5 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.